Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease

NCT00909545 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

99

Enrollment

OTHER

Sponsor class

Conditions

Parkinson Disease

Interventions

DRUG: Isradipine CR 5mg
DRUG: Isradipine CR 10mg
DRUG: Isradipine CR 20mg
DRUG: Placebo

Sponsor

Northwestern University

Collaborators

[object Object]
[object Object]
[object Object]